Ascendis Pharma AS Total Assets
Ascendis Pharma AS total assets. Based on the latest financial reports, Ascendis Pharma AS (ASND) holds total assets worth $2.01 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Ascendis Pharma AS (ASND) total market value for the company's overall valuation and market capitalisation.
Total Assets of Ascendis Pharma AS (2011–2025)
Total assets of Ascendis Pharma AS from 2011 to 2025. This chart illustrates how Ascendis Pharma AS's total assets have evolved over time, based on quarterly financial data. See ASND stock price for real-time trading data and today's change.
Ascendis Pharma AS - Asset Composition Analysis
Ascendis Pharma AS Total Assets Breakdown (December 2025)
Ascendis Pharma AS total assets breakdown as of December 2025. Ascendis Pharma AS's total assets of $2.01 Billion consist of 85.1% current assets and 14.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 47.3% |
| Accounts Receivable | $157.63 Million | 12.1% |
| Inventory | $301.40 Million | 23.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $214.91K | 0.0% |
| Goodwill | $3.49 Million | 0.3% |
Asset Composition Trend (2011–2025)
This chart illustrates how Ascendis Pharma AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Ascendis Pharma AS short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ascendis Pharma AS's current assets represent 85.1% of total assets in 2025, an increase from 78.8% in 2011.
- Cash Position: Cash and equivalents constituted 47.3% of total assets in 2025, down from 68.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 15.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 23.2% of total assets.
Ascendis Pharma AS Competitors by Total Assets
Key competitors of Ascendis Pharma AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Ascendis Pharma AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.00 | 1.04 | 8.31 |
| Quick Ratio | 0.72 | 0.71 | 8.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-4.43 Million | $35.98 Million | $513.95 Million |
Ascendis Pharma AS - Advanced Valuation Insights
This section examines the relationship between Ascendis Pharma AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 25.71 |
| Latest Market Cap to Assets Ratio | 11.32 |
| Asset Growth Rate (YoY) | 10.4% |
| Total Assets | $1.30 Billion |
| Market Capitalization | $14.74 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ascendis Pharma AS's assets at a significant premium (11.32x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Ascendis Pharma AS's assets grew by 10.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ascendis Pharma AS (2011–2025)
The table below shows the annual total assets of Ascendis Pharma AS from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.30 Billion | +10.39% |
| 2024-12-31 | $1.18 Billion | +42.87% |
| 2023-12-31 | $825.59 Million | -24.24% |
| 2022-12-31 | $1.09 Billion | +0.44% |
| 2021-12-31 | $1.08 Billion | +10.73% |
| 2020-12-31 | $979.79 Million | +44.78% |
| 2019-12-31 | $676.73 Million | +112.16% |
| 2018-12-31 | $318.97 Million | +51.18% |
| 2017-12-31 | $210.98 Million | +11.00% |
| 2016-12-31 | $190.07 Million | +44.24% |
| 2015-12-31 | $131.77 Million | +124.60% |
| 2014-12-31 | $58.67 Million | +119.74% |
| 2013-12-31 | $26.70 Million | +5.10% |
| 2012-12-31 | $25.41 Million | +11.34% |
| 2011-12-31 | $22.82 Million | -- |
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more